Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil for excessive sleepiness after mild or moderate closed traumatic brain injury
2009-014545-83Phase 3Terminated
- Sponsor
- Cephalon, Inc.
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of armodafinil in Excessive Daytime Sleepiness (EDS) and traumatic brain injury (TBI) (4 arms), sponsored by Cephalon, Inc. Primary endpoints: Mean sleep latency on Multiple Sleep Latency Test and Clinical Global Impression of Change responder rate. Started Jan 2010; status: terminated.
02
Drugs
armodafinil
03
Conditions
Excessive Daytime Sleepiness (EDS)traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2009-014545-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014545-83.